Diphtheria Toxoid / Haemophilus B Conjugate (Prp-T) Vaccine / Pertussis, Acellular / Poliovirus Vaccine, Inactivated / Tetanus Toxoid Dosage

Usual Pediatric Dose for Haemophilus influenzae Prophylaxis

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Poliomyelitis Prophylaxis

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Diphtheria Prophylaxis

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Pertussis Prophylaxis

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Tetanus Prophylaxis

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Pentacel is supplied in two vials; be sure to administer the contents of both vials as directed in package labeling.

Dialysis

Data not available